NovoCure reports Q2 revenue up 16% to $184M, raises 2026 guidance, receives EU approval for Optune Pax

Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 net revenues of $183.6M, up 16% YoY, driven by 18% global active patient growth to 5,128 patients; gross margin improved to 78% (vs. 74% prior year) including a one-time $4.9M tariff refund.

  Exhibit 99.1 view on EDGAR →
• high

  Raised full-year 2026 revenue guidance to $710-725M (from $690-710M) and Adjusted EBITDA guidance to $0-15M (from negative $15-0M), reflecting stronger patient growth and profitability trajectory.

  Exhibit 99.1 view on EDGAR →
• high

  Received CE Mark approval in June 2026 for Optune Pax in Europe for locally advanced pancreatic cancer; Germany will be first EU market to launch. U.S. had 285 active Optune Pax patients as of June 30.

  Exhibit 99.1 view on EDGAR →